Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression

Although Y‐box binding protein‐1 (YB‐1) is known to be overexpressed in prostate cancer, especially castration‐resistant prostate cancer (CRPC), the mechanism of its overexpression remains unclear. We aimed to elucidate the mechanism of YB‐1 overexpression in CRPC. Gene amplification in CRPC cells and tissues was examined by public database analysis, and digital PCR. The significance of YB‐1 amplification for the YB‐1/androgen receptor (AR) axis and prognosis was examined by public database analysis and immunohistochemistry. YB‐1 amplification was mainly observed in CRPC tissues by public database analysis and confirmed in CRPC cells and tissues by digital PCR. Expression of YB‐1 was increased in CRPC tissues compared with treatment‐naïve tissues. Furthermore, YB‐1 and phosphorylated YB‐1 levels were associated with AR and AR V7 expression levels. Finally, YB‐1 amplification was associated with poor outcomes in CRPC. Taken together, the present findings suggest that YB‐1 amplification contributes to progression to CRPC through regulation of AR and AR V7 expressions, and that YB‐1 is a promising therapeutic target in CRPC.

[1]  Angela N. Brooks,et al.  Visualizing and interpreting cancer genomics data via the Xena platform , 2020, Nature Biotechnology.

[2]  Christopher S. Hughes,et al.  Class I HDAC inhibitors enhance YB‐1 acetylation and oxidative stress to block sarcoma metastasis , 2019, EMBO reports.

[3]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[4]  Qiang Zhou,et al.  Nimotuzumab inhibits epithelial–mesenchymal transition in prostate cancer by targeting the Akt/YB‐1/AR axis , 2019, IUBMB life.

[5]  S. Chiu,et al.  Fisetin targets YB-1/RSK axis independent of its effect on ERK signaling: insights from in vitro and in vivo melanoma models , 2018, Scientific Reports.

[6]  Adrian V. Lee,et al.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.

[7]  G. Sauter,et al.  Up regulation and nuclear translocation of Y-box binding protein 1 (YB-1) is linked to poor prognosis in ERG-negative prostate cancer , 2017, Scientific Reports.

[8]  Cheng Li,et al.  GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses , 2017, Nucleic Acids Res..

[9]  Y. Oda,et al.  Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7. , 2016, Journal of the National Cancer Institute.

[10]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[11]  Y. Oda,et al.  Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer. , 2015, Endocrine-related cancer.

[12]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[13]  C. Galet,et al.  YB-1 and MTA1 protein levels and not DNA or mRNA alterations predict for prostate cancer recurrence , 2015, Oncotarget.

[14]  W. Isaacs,et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. , 2014, The New England journal of medicine.

[15]  T. Uchiumi,et al.  Targeting ribosomal S6 kinases/Y‐box binding protein‐1 signaling improves cellular sensitivity to taxane in prostate cancer , 2014, The Prostate.

[16]  T. Uchiumi,et al.  Inhibition of RSK/YB‐1 signaling enhances the anti‐cancer effect of enzalutamide in prostate cancer , 2014, The Prostate.

[17]  P. Nelson,et al.  Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer , 2014, Clinical Cancer Research.

[18]  T. Uchiumi,et al.  Inhibition of Protein Kinase C/Twist1 Signaling Augments Anticancer Effects of Androgen Deprivation and Enzalutamide in Prostate Cancer , 2013, Clinical Cancer Research.

[19]  K. Kuroiwa,et al.  Mutual Regulation between Raf/MEK/ERK Signaling and Y-Box–Binding Protein-1 Promotes Prostate Cancer Progression , 2013, Clinical Cancer Research.

[20]  P. Nelson,et al.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. , 2012, Cancer research.

[21]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[22]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[23]  K. Kuroiwa,et al.  Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. , 2012, The Journal of urology.

[24]  Seiji Naito,et al.  Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer. , 2011, Free radical biology & medicine.

[25]  P. Nelson,et al.  Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants , 2011, Clinical Cancer Research.

[26]  M. Shiota,et al.  Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. , 2011, Journal of molecular endocrinology.

[27]  K. Kuroiwa,et al.  Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression. , 2011, Endocrine-related cancer.

[28]  M. Sadar.  Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. , 2011, Cancer research.

[29]  W. Dahut,et al.  An update on androgen deprivation therapy for prostate cancer. , 2010, Endocrine-related cancer.

[30]  D. Albertson,et al.  Gene amplification in cancer. , 2006, Trends in genetics : TIG.

[31]  K. Yasumoto,et al.  The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. , 2004, Molecular cancer therapeutics.

[32]  M. Gleave,et al.  YB‐1 is upregulated during prostate cancer tumor progression and increases P‐glycoprotein activity , 2004, The Prostate.

[33]  H. Izumi,et al.  The pleiotropic functions of the Y-box-binding protein, YB-1. , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[34]  T. Uchiumi,et al.  Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression , 2010, Oncogene.

[35]  H. Izumi,et al.  Twist promotes tumor cell growth through YB-1 expression. , 2008, Cancer research.